FDA Approves Leucovorin for Rare Genetic Condition, Not Autism Treatment

The FDA has approved leucovorin, a high-dose B vitamin, specifically for treating cerebral folate deficiency in the receptor 1 gene, a rare genetic disorder affecting approximately 1 in 1 million people. This decision comes after a previous White House briefing where officials suggested the drug could benefit children with autism, leading to a surge in prescriptions. However, the FDA clarified that there was insufficient evidence to support its efficacy for autism. Families, particularly those of children with autism, are feeling the impact of this decision, as many had begun using the drug based on earlier statements, and now face challenges in obtaining it. Parents express frustration over the administration's premature claims regarding the drug's potential benefits for autism.

Key Details: • Leucovorin is approved only for cerebral folate deficiency, not autism. • Less than 50 cases of this rare genetic condition have been identified globally. • Parents are experiencing difficulties in obtaining leucovorin prescriptions. • Concerns arise regarding insurance coverage for the medication after FDA's decision.